Comparative Pharmacology
Head-to-head clinical analysis: HAILEY 24 FE versus QUARTETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY 24 FE versus QUARTETTE.
HAILEY 24 FE vs QUARTETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone; inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination oral contraceptive containing drospirenone, ethinyl estradiol, levomefolate calcium, and metformin. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. Ethinyl estradiol is an estrogen. Levomefolate calcium is a folate supplement. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity.
One tablet orally once daily for 24 weeks. Each tablet contains norethindrone 0.8 mg and ethinyl estradiol 0.02 mg. After 24 weeks, take one inactive (ferrous fumarate) tablet daily for 4 weeks. Total cycle: 28 tablets.
3 mg orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol has a terminal half-life of approximately 13-27 hours (mean 18.5 hours). Norethindrone has a terminal half-life of approximately 8-12 hours. The half-life supports once-daily dosing.
Terminal elimination half-life is 12-14 hours; clinically this supports once-daily dosing with steady state achieved within 2-3 days.
Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone is excreted in urine (30-50%) and feces (20-30%) as metabolites.
Renal excretion accounts for 55% (primarily as unchanged drug), biliary/fecal excretion 35%, and the remainder undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive